Bcl-2 gene therapy - Idun/Selective Genetics
Latest Information Update: 17 Aug 2006
At a glance
- Originator Idun Pharmaceuticals; Tissue Repair Company
- Class Anti-ischaemics; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Fracture; Ischaemic heart disorders; Skin ulcer; Spinal cord injuries
Most Recent Events
- 05 Dec 2003 No development reported - Preclinical for Fracture in USA (unspecified route)
- 05 Dec 2003 No development reported - Preclinical for Ischaemic heart disorders in USA (unspecified route)
- 05 Dec 2003 No development reported - Preclinical for Skin ulcer in USA (unspecified route)